Skip to content

Mechanism and Clinical Study of TRPV4-Shh-Mediated Artesunate Repair of Mucosal Barrier in Interstitial Cystitis

Mechanism and Clinical Study of TRPV4-Shh-Mediated Artesunate Repair of Mucosal Barrier in Interstitial Cystitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116367
Enrollment
Unknown
Registered
2026-01-08
Start date
2026-01-10
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial cystitis

Interventions

Control group:None
Cystitis group:None

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 80 years, regardless of gender; 2.Patients clinically diagnosed with cystitis or bladder cancer, with pre-enrollment pathological histological or cytological examination confirmed by two or more pathologists; 3. Complete medical records during the study period: age at diagnosis, BMI, comorbidities, family history; pre-treatment blood routine, albumin and prealbumin, CRP, D-dimer, and imaging data; intraoperative findings, post-operative pathological examination of the primary lesion size and location, etc.

Exclusion criteria

Exclusion criteria: 1. Age less than 18 years or greater than 80 years; 2.Suffering from other serious urinary system diseases, such as renal failure, urinary tract infection, etc; 3.Having serious systemic diseases, such as cardiovascular disease, abnormal liver function, etc; 4. Lacking key data (such as pathology reports, symptom scores, etc.); 5. Having active infectious diseases such as HIV, hepatitis B, hepatitis C, or active rheumatic diseases; 6. The investigator deems the patient unsuitable for enrollment, for example, having a serious or uncontrolled bacterial, fungal, or viral infection that may interfere with the patient's participation in this study or evaluation of the study results; 7. The patient is lost to follow-up without justifiable reason during the study; 8. The patient or their family refuses to participate in this study.

Design outcomes

Primary

MeasureTime frame
Bladder symptom score;Bladder function index;Repair of bladder mucosal barrier;

Secondary

MeasureTime frame
Quality of life score;Incidence of adverse events;Blood and urine biochemical indicators;

Countries

China

Contacts

Public ContactYanyuan Wu

Zhejiang Cancer Hospital

wuyy@zjcc.org.cn+86 571 88128032

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026